Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00943917 · ClinicalTrials.gov registry record · Phase 2
Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Intarcia Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 155
- Enrollment target
NCT00943917: Completed Phase 2 study, sponsored by Intarcia Therapeutics.
NCT00943917 is a Phase 2 study that has completed, run by Intarcia Therapeutics. The registered enrollment target is 155 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00943917, a Phase 2 study, has completed, sponsored by Intarcia Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 155 participants
- Enrollment target
Study Summary
The purpose of this study is to determine safety, efficacy and tolerability of various doses of ITCA 650 in subjects with type 2 diabetes.
Primary Outcome
Mean change in HbA1c over first 12 weeks (Stage I)
Interventions
- DRUG Exenatide Injection
- OTHER ITCA 650
- OTHER Ex Inj/ITCA 650
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2009-08 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
What the finished NCT00943917 record still lists
NCT00943917 is an interventional study that assigns participants to a tested intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% higher).
The record links to 0 conditions, and to 3 interventions - of which Exenatide Injection is the first listed.
NCT00943917 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00943917 about?
NCT00943917 is a clinical study titled "Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus". The purpose of this study is to determine safety, efficacy and tolerability of various doses of ITCA 650 in subjects with type 2 diabetes.
What is the current status of trial NCT00943917?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2009-08. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00943917?
The interventions under investigation include: Exenatide Injection (DRUG), ITCA 650 (OTHER), Ex Inj/ITCA 650 (OTHER).
Who is sponsoring clinical trial NCT00943917?
This trial is sponsored by Intarcia Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00943917's enrollment target sits among peer trials
155 448th of 2000 higher than 1,553 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03223610 · 155 participants · Phase 1
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- NCT05072483 · 155 participants
Natural History Study of CADASIL
- NCT05086497 · 155 participants · NA
WBSI Guided Personalized Delivery of TTFields
- NCT05412069 · 155 participants · NA
Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia